Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Michael Meister

Pediatric Oncologist / PhD student
Michael Meister
Michael Meister
Soft tissue sarcomas

I joined the Princess Máxima Center as a basic researcher and pediatrician in training in June 2018. My primary research interest lies in understanding the molecular biology of pediatric soft tissue sarcomas (STS) and to use that knowledge to develop new treatment options for patients suffering from these tumors. To this end, I study establishment procedures for novel preclinical models of pediatrist STS (i.e., tumor organoid models) as well as bulk and single-cell genomics of these tumors. I am furthermore member of the molecular tumor board of the Dutch iTHER as well as the German INFORM pediatric precision medicine trial.

  • Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

    • aug. 2022
    • Michael T, Meister, et al
    • EMBO molecular medicine
  • Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells

    • feb. 2022
    • Ufuk, Erdogdu, et al
    • Neoplasia (New York, N.Y.)
  • The Pediatric Precision Oncology INFORM Registry

    • nov. 2021
    • Cornelis M, van Tilburg, et al
    • Cancer discovery
  • Malignant peripheral nerve sheath tumors in children, adolescents, and young adults

    • dec. 2020
    • , et al
    • Journal of surgical oncology
  • Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells

    • mei 2020
    • Cathinka, Boedicker, et al
    • Oncogene
View all publications